JJJo-Ann M. Md Johnson

Jo-Ann M. Md Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jo-Ann M. Md Johnson has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • A Metcalfe

    Obstetrics and Gynecology University of British Columbia Vancouver BC Canada

    1 shared publication
  • A. Metcalfe

    Department of Obstetrics and Gynecology University of Calgary Calgary Alberta Canada

    1 shared publication
  • D Wilson

    Obstetrics and Gynecology University of Calgary Calgary AB Canada

    1 shared publication
  • David A. Md Omahen

    Department of Obstetrics & Gynecology and Department of Clinical Neurosciences, Foothills Hospital, Faculty of Medicine, University of Calgary, Calgary, Alberta and the Department of Neurosurgery, Royal Inland Hospital, Kamloops Britsh Columbia, Canada

    1 shared publication
  • G Connors

    Obstetrics and Gynecology University of Calgary Calgary AB Canada

    1 shared publication
  • G. Clarke

    Canadian Blood Services and Department of Laboratory Medicine and Pathology University of Alberta Edmonton Alberta Canada

    1 shared publication

Latest Publications

  • Costs and benefits of non‐invasive fetal RhD determination

    by L. Teitelbaum, A. Metcalfe, G. Clarke, J. S. Parboosingh, R. D. Wilson, J. M. Johnson

    Objective: Non‐invasive fetal Rhesus (Rh) D genotyping, using cell‐free fetal DNA (cffDNA) in the maternal blood, allows targeted antenatal anti‐RhD prophylaxis in unsensitized RhD‐negative pregnant women. The purpose of this study was to determine the cost and benefit of this approach as compared to routine antenatal anti‐RhD prophylaxis for all unsensitized RhD‐negative pregnant women, as is the current policy in the province of Alberta, Canada.Methods: This study was a decision analysis based on a theoretical population representing the total number of pregnancies in Alberta over a 1‐year period (n = 69 286). A decision tree was created that outlined targeted prophylaxis for unsensitized RhD‐negative pregnant women screened for cffDNA (targeted group) vs routine prophylaxis for all unsensitized RhD‐negative pregnant women (routine group). Probabilities at each decision point and costs associated with each resource were calculated from local clinical and administrative data. Outcomes measured were cost, number of women sensitized and doses of Rh immunoglobulin (RhIG) administered.Results: The estimated cost per pregnancy for the routine group was 71.43 compared with 67.20 Canadian dollars in the targeted group. The sensitization rates per RhD‐negative pregnancy were equal, at 0.0012, for the current and targeted programs. Implementing targeted antenatal anti‐RhD prophylaxis would save 4072 doses (20.1%) of RhIG over a 1‐year period in Alberta when compared to the current program.Conclusions: These data support the feasibility of a targeted antenatal anti‐RhD prophylaxis program, at a lower cost than that of the existing routine prophylaxis program, with no increased risk of sensitization. Copyright © 2014 ISUOG. Published by John Wiley & Sons Ltd.


  • Open Access

    First‐trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell‐free DNA

    by J Johnson, M Pastuck, A Metcalfe, G Connors, R Krause, D Wilson, H Cuckle

    Objective: This study aimed to evaluate serum‐only four‐marker first trimester (1T‐Quad) Down syndrome screening, alone or contingently to select 10–20% with highest risk for nuchal translucency (NT) or cell‐free (cf)DNA.Methods: Stored maternal serum samples (−80 °C) from 90 pregnancies with fetal Down syndrome and 1607 controls were retrieved and measured for placental growth factor, α‐fetoprotein, pregnancy‐associated plasma protein and free β‐human chorionic gonadotropin. Samples were from singleton pregnancies (9–13 + 6 weeks), and NT was measured between 11 and 13 + 6 weeks. Markers were expressed in multiples of the normal median (MoM) for gestation. Gaussian models were fitted to the distribution of log MoMs by using observed parameters, standardized maternal age distribution (mean 27, SD 5.5) and published cfDNA results.Results: The model‐predicted detection rate (DR) for 1T‐Quad was 74% [5% false‐positive rate (FPR)]. When used contingently to select for NT, the DR was 89% at 5%. When used to select for cfDNA, the DR was 91% (FPR < 0.05%).Conclusion: The 1T‐Quad test can achieve a similar DR to a second‐trimester Quad test. When used contingently to select for NT, the DR is similar to the Combined test. Used contingently to select for cfDNA would achieve even higher detection. © 2013 John Wiley & Sons, Ltd.


  • Recurrent Exophytic Meningioma in Pregnancy

    by Michelle S. Bsc(Hons) Chow, Philippe A. Mercier, David A. Md Omahen, Stephen L. Msc Wood, Jo-Ann M. Md Johnson

    BACKGROUND: Meningiomas are slow-growing tumors that may present in pregnancy because of accelerated growth. We present the case of a recurrent meningioma in two separate pregnancies in the same woman. CASE: A 35-year-old woman presented at 30 weeks of gestation with limb weakness, vomiting, and a progressive decreased level of consciousness with an enlarging forehead mass. Imaging revealed a massive extra-axial exophytic tumor. An emergency craniotomy was performed, complicated by massive blood loss. Final pathology showed a grade I meningioma positive for progesterone receptors. Maternal–fetal outcome was good, with return of normal neurologic status and elective delivery at 38 weeks of gestation. CONCLUSION: Pregnancy is associated with accelerated meningioma growth and recurrence. Treatment during pregnancy is possible and requires a multidisciplinary approach.